FRONT ONCOL 润色咨询

Frontiers in Oncology

出版年份:2011 年文章数:14479 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:2.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2023-04-28 ms1000001631708013 来自浙江省

    审稿速度:2.0 | 投稿命中率:75.0
    偏重的研究方向:肿瘤;生信
    经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!
    11 Apr 2023 Article accepted for publication.
    07 Apr 2023 Review of Review Editor 3 finalized.
    01 Apr 2023 Review of Review Editor 4 finalized.
    30 Mar 2023 Review of Review Editor 1 finalized.
    17 Mar 2023 Interactive review forum activated.
    07 Feb 2023 submitted manuscript

    7

    展开7条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2021-09-17 146e0980m70暂无昵称

    审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0
    偏重的研究方向:肿瘤
    经验分享:来还愿了
    修回3天后审稿人全部endorse
    第4天就直接accept了
    从投稿到接收差不多两个月左右,这个速度简直感激

    72

    展开72条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2024-06-08 胸外科小大夫 来自辽宁省

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤;非小细胞肺癌
    经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2022-04-25 12133f96m16(暂无昵称)

    editors assiment阶段就in review??什么情况

    7

    展开7条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2024-05-06 jm7009 来自河南省

    这个投稿快一个月了,还一直在编辑手中,怎么办啊

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2023-07-08 一梦十寒 来自湖北省

    偏重的研究方向:肺癌
    经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的

    2

    展开2条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2023-05-10 ms606531017093482 来自重庆

    目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?

    7

    展开7条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2023-10-30 小鹏友 来自重庆

    审稿速度:3.0 | 投稿命中率:95.0
    偏重的研究方向:肿瘤
    经验分享:非常水……😌😌😌😌

    7

    展开7条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2024-05-02 吕心小可爱 来自广东省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:肿瘤细胞免疫
    经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。
    02 May 2024 Article accepted for publication.
    29 Apr 2024
    Submitting Author ** posted new comments in the Editor tab.(当天修回)
    Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)
    27 Apr 2024 Review of Review Editor 2 finalized.
    23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.
    12 Apr 2024 Interactive review forum activated automatically.
    07 Apr 2024 Reviewer 2: Minor revision is required.
    07 Mar 2024 Review of Reviewer 1 is finalized.
    08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.
    25 Nov 2023 Submitting Author ** resubmitted the manuscript.
    23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)
    22 Nov 2023 Submitting Author ** submitted manuscript.

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2129118, encodeId=7b09212911888, content=审稿速度:2.0 | 投稿命中率:75.0<br>偏重的研究方向:肿瘤;生信<br>经验分享:还是比较好投的,2月多投的,4月多就接受了;祝大家好运!<br>11 Apr 2023 Article accepted for publication.<br>07 Apr 2023 Review of Review Editor 3 finalized.<br>01 Apr 2023 Review of Review Editor 4 finalized.<br>30 Mar 2023 Review of Review Editor 1 finalized.<br>17 Mar 2023 Interactive review forum activated.<br>07 Feb 2023 submitted manuscript, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=118, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b966155723, createdName=ms1000001631708013, createdTime=Fri Apr 28 21:51:41 CST 2023, time=2023-04-28, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1052409, encodeId=26df105240933, content=审稿速度:2.0 | 投稿命中率:75.0 | 版面费用:2950.0<br>偏重的研究方向:肿瘤<br>经验分享:来还愿了<br>修回3天后审稿人全部endorse<br>第4天就直接accept了<br>从投稿到接收差不多两个月左右,这个速度简直感激, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=313, replyNumber=72, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=fb605173656, createdName=146e0980m70暂无昵称, createdTime=Fri Sep 17 20:59:04 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2208898, encodeId=09ea220889850, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤;非小细胞肺癌<br>经验分享:Received date: 22 Mar 2024 Editorial assignment start date: 25 Mar 2024 Independent review start date: 09 Apr 2024 Review finalized date: 27 May 2024 Final validation date: 06 Jun 2024 2个半月,建议推荐审稿人。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20221102/369591c85731477baa49cc9e4607aa59/710024ddb86e4cc79b2f2a73449bbb88.jpg, createdBy=041e5339211, createdName=胸外科小大夫, createdTime=Sat Jun 08 04:34:14 CST 2024, time=2024-06-08, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=1214041, encodeId=a90f12140419a, content=editors assiment阶段就in review??什么情况, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=32c32236172, createdName=12133f96m16(暂无昵称), createdTime=Mon Apr 25 08:49:30 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2201986, encodeId=04b1220198613, content=这个投稿快一个月了,还一直在编辑手中,怎么办啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=18, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKcZDpJe6MqBsOtgBUOqlJPmiaWChJwP0vfBOPzVJKAjp6qWkO3AkXU25ficibbCiaI9fCQqsoFiaOvLkw/132, createdBy=66992508745, createdName=jm7009, createdTime=Mon May 06 11:46:16 CST 2024, time=2024-05-06, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2146948, encodeId=03e621469485a, content=偏重的研究方向:肺癌<br>经验分享:感觉今年有点抽风,两个审稿人给小修,编辑发邮件建议拒稿,但系统里提前需要修改,给了六天时间回复意见,准备返修回去后rebuttal,铁子们,有没有同样情况的 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKbuMTogxT82iaafNzKneXa0pOJ6F14K57vK0W8Loxkibl2ZfjgtmlJbEFbpIv4qpjuqhhoK05tzibWw/132, createdBy=89622105481, createdName=一梦十寒, createdTime=Sat Jul 08 10:57:52 CST 2023, time=2023-07-08, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2131464, encodeId=9f8d2131464c9, content=目前在live chat 显示The manuscript is provisionally accepted. The editorial office is completing a final round of technical checks。需要等多久才知道被正式录用啊?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=68, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9de1913859, createdName=ms606531017093482, createdTime=Wed May 10 22:20:56 CST 2023, time=2023-05-10, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2165771, encodeId=1b102165e71cf, content=审稿速度:3.0 | 投稿命中率:95.0<br>偏重的研究方向:肿瘤<br>经验分享:非常水……😌😌😌😌, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=66, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ace2342720, createdName=小鹏友, createdTime=Mon Oct 30 18:20:01 CST 2023, time=2023-10-30, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2201491, encodeId=ed302201491a9, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:肿瘤细胞免疫<br>经验分享:分享一下投稿经历,历时6个月,主要是Initial Validation阶段太长了,由于之前已经有文章可以满足毕业要求了,便没催过编辑,希望看到的人(尤其是需要文章毕业的小伙伴)都能中。<br>02 May 2024 Article accepted for publication.<br>29 Apr 2024 <br>Submitting Author ** posted new comments in the Editor tab.(当天修回)<br>Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to revise the manuscript.(审稿人1同意直接发表,便没有回复,看来还是需要把所有审稿人的意见都回复一下)<br>27 Apr 2024 Review of Review Editor 2 finalized.<br>23 Apr 2024 Submitting Author ** re-submitted manuscript. You posted new comments.<br>12 Apr 2024 Interactive review forum activated automatically.<br>07 Apr 2024 Reviewer 2: Minor revision is required.<br>07 Mar 2024 Review of Reviewer 1 is finalized.<br>08 Feb 2024 Manuscript transferred from Frontiers in Oncology, section Thoracic Oncology, research topic: None to Frontiers in Oncology, section Cancer Immunity and Immunotherapy, research topic: None.<br>25 Nov 2023 Submitting Author ** resubmitted the manuscript.<br>23 Nov 2023 Editorial Office Frontiers in Oncology Editorial Office requested Corresponding/Submitting Author to resubmit their manuscript.(要求提交原始数据)<br>22 Nov 2023 Submitting Author ** submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=75ea8794060, createdName=吕心小可爱, createdTime=Thu May 02 18:39:14 CST 2024, time=2024-05-02, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2195332, encodeId=2bf121953327a, content=偏重的研究方向:肿瘤<br>经验分享:各位大佬,请问这个拒稿意见是什么意思啊?<br>Reason:<br>Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=27, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0f279231064, createdName=ms1000000764624599, createdTime=Mon Mar 25 22:43:40 CST 2024, time=2024-03-25, status=1, ipAttribution=贵州省)]
    2024-03-25 ms1000000764624599 来自贵州省

    偏重的研究方向:肿瘤
    经验分享:各位大佬,请问这个拒稿意见是什么意思啊?
    Reason:
    Issues related to compliance with research integrity policies, journal guidelines, or any other essential editorial criteria were identified in this manuscript that prevent further review or publication.

    2

    展开2条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分